Last reviewed · How we verify
PTC Therapeutics — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
3 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Ataluren (PTC124®) | Ataluren (PTC124®) | phase 3 | Nonsense suppression agent | Ribosome (eukaryotic translation machinery) | Rare genetic diseases | |
| PTC923 | PTC923 | phase 3 | Pyruvate dehydrogenase kinase (PDK) inhibitor | PDK (pyruvate dehydrogenase kinase) | Rare genetic/metabolic disorders |
Therapeutic area mix
- Rare Diseases · 1
- Rare genetic diseases · 1
- Rare genetic/metabolic disorders · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- National Health Research Institutes, Taiwan · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for PTC Therapeutics:
- PTC Therapeutics pipeline updates — RSS
- PTC Therapeutics pipeline updates — Atom
- PTC Therapeutics pipeline updates — JSON
Cite this brief
Drug Landscape (2026). PTC Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ptc-therapeutics. Accessed 2026-06-10.